Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Paoletti

Showing results (101-110 of 145) with videos related to

Pageof 15
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 20, 2021
First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trialRaphael J Morscher, Caroline Brard, Pablo Berlanga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2024
Evolution of the Innovative Therapies for Children With Cancer Consortium Trial Portfolio for Drug Development for Children With CancerFrancisco Bautista, Jaime Verdú-Amorós, Birgit Geoerger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2021
Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART TrialFrancisco Bautista, Xavier Paoletti, Jonathan Rubino, et al.
Therapie|December 18, 2022
Platform trialsMatthieu Roustit, Olivier Demarcq, Silvy Laporte, et al.
The Journal of Pathology|October 6, 2021
Multilayer spectrum of intratumoral heterogeneity in basal bladder cancerNanor Sirab, Damien Drubay, Pascale Maillé, et al.
Therapie|December 29, 2022
Matthieu Roustit, Olivier Demarcq, Silvy Laporte, et al.
Therapie|February 18, 2020
Michel Cucherat, Silvy Laporte, Olivier Delaitre, et al.
Therapie|February 18, 2020
From single-arm studies to externally controlled studies. Methodological considerations and guidelinesMichel Cucherat, Silvy Laporte, Olivier Delaitre, et al.
Plos One|October 19, 2021
Using a new diagnostic tool to predict lymph node metastasis in advanced epithelial ovarian cancer leads to simple lymphadenectomy decision rules: A multicentre study from the FRANCOGYN groupCamille Mimoun, Xavier Paoletti, Thomas Gaillard, et al.
European Journal of Cancer (Oxford, England : 1990)|June 2, 2014
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led studySophie Postel-Vinay, Laurence Collette, Xavier Paoletti, et al.
Pageof 15

Showing results (101-110 of 145) with videos related to

Sort By:
Pageof 15
European Journal of Cancer (Oxford, England : 1990)|September 20, 2021
First-in-child phase I/II study of the dual mTORC1/2 inhibitor vistusertib (AZD2014) as monotherapy and in combination with topotecan-temozolomide in children with advanced malignancies: arms E and F of the AcSé-ESMART trialRaphael J Morscher, Caroline Brard, Pablo Berlanga, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 14, 2024
Evolution of the Innovative Therapies for Children With Cancer Consortium Trial Portfolio for Drug Development for Children With CancerFrancisco Bautista, Jaime Verdú-Amorós, Birgit Geoerger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 4, 2021
Phase I or II Study of Ribociclib in Combination With Topotecan-Temozolomide or Everolimus in Children With Advanced Malignancies: Arms A and B of the AcSé-ESMART TrialFrancisco Bautista, Xavier Paoletti, Jonathan Rubino, et al.
Therapie|December 18, 2022
Platform trialsMatthieu Roustit, Olivier Demarcq, Silvy Laporte, et al.
The Journal of Pathology|October 6, 2021
Multilayer spectrum of intratumoral heterogeneity in basal bladder cancerNanor Sirab, Damien Drubay, Pascale Maillé, et al.
Therapie|December 29, 2022
Matthieu Roustit, Olivier Demarcq, Silvy Laporte, et al.
Therapie|February 18, 2020
Michel Cucherat, Silvy Laporte, Olivier Delaitre, et al.
Therapie|February 18, 2020
From single-arm studies to externally controlled studies. Methodological considerations and guidelinesMichel Cucherat, Silvy Laporte, Olivier Delaitre, et al.
Plos One|October 19, 2021
Using a new diagnostic tool to predict lymph node metastasis in advanced epithelial ovarian cancer leads to simple lymphadenectomy decision rules: A multicentre study from the FRANCOGYN groupCamille Mimoun, Xavier Paoletti, Thomas Gaillard, et al.
European Journal of Cancer (Oxford, England : 1990)|June 2, 2014
Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents--dose-Limiting Toxicity and Toxicity Assessment Recommendation Group for Early Trials of Targeted therapies, an European Organisation for Research and Treatment of Cancer-led studySophie Postel-Vinay, Laurence Collette, Xavier Paoletti, et al.
Pageof 15